Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients

European Journal of Cancer

Volumn 45, Issue 3, 2009, Pages 478-489

  Gutwein, Paul ^a,i   Schramme, Anja ^a,i   Sinke, Nina ^a,i   Abdel Bakky, Mohamed Sadek ^a   Voss, Beren ^a   Obermüller, Nicholas ^b   Doberstein, Kai ^a   Koziolek, Michael ^c   Fritzsche, Florian ^d   Johannsen, Manfred ^e   Jung, Klaus ^e   Schaider, Helmut ^f   Altevogt, Peter ^g   Ludwig, Andreas ^h   Pfeilschifter, Josef ^a,i   Kristiansen, Glen ^d,i  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

ⁱ NONE

Author keywords

ADAM10; CXCL16; CXCR6; Renal cancer; Renal cancer tissue

Indexed keywords

ADAM 10 PROTEIN; ADAM PROTEIN; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING;

ADAM PROTEINS; ADULT; AMYLOID PRECURSOR PROTEIN SECRETASES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHEMOKINES, CXC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; RECEPTORS, CHEMOKINE; RECEPTORS, SCAVENGER; RECEPTORS, VIRUS; TUMOR MARKERS, BIOLOGICAL;

EID: 59349091119     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.023     Document Type: Article

References (34)

1. Drucker B.J. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31 (2005) 536-545
2. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 166 (2001) 1611-1623
3. Tanaka T., Bai Z., Srinoulprasert Y., et al. Chemokines in tumor progression and metastasis. Cancer Sci 96 (2005) 317-322
4. Gao J.Q., Sugita T., Kanagawa N., et al. Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector. Biol Pharm Bull 28 (2005) 1066-1070
5. Sharma S., Yang S.C., Hillinger S., et al. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2 (2003) 22
6. Hojo S., Koizumi K., Tsuneyama K., et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 67 (2007) 4725-4731
7. Hundhausen C., Schulte A., Schulz B., et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 178 (2007) 8064-8072
8. Ludwig A., Schulte A., Schnack C., et al. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem 93 (2005) 1293-1303
9. Scholz F., Schulte A., Adamski F., et al. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin. J Invest Dermatol 127 (2007) 1444-1455
10. Wagsater D., Hugander A., and Dimberg J. Expression of CXCL16 in human rectal cancer. Int J Mol Med 14 (2004) 65-69
11. Shimaoka T., Nakayama T., Fukumoto N., et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 75 (2004) 267-274
12. Abel S., Hundhausen C., Mentlein R., et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172 (2004) 6362-6372
13. Ludwig A., Hundhausen C., Lambert M.H., et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 8 (2005) 161-171
14. Morris M.R., Gentle D., Abdulrahman M., et al. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Brit J Cancer 98 (2008) 496-501
15. Kristiansen G., Yu Y., Petersen S., et al. Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer 37 (2001) 1089-1095
16. Schmidt-Zachmann M.S., Knecht S., and Kramer A. Molecular characterization of a novel, widespread nuclear protein that colocalizes with spliceosome components. Mol Biol Cell 9 (1998) 143-160
17. Wiechen K., Diatchenko L., Agoulnik A., et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159 (2001) 1635-1643
18. Schramme A., Abdel-Bakky M.S., Gutwein P., et al. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int (2008)
19. Elbashir S.M., Harborth J., Lendeckel W., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
20. Mechtersheimer S., Gutwein P., Agmon-Levin N., et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155 (2001) 661-673
21. Schulte A., Schulz B., Andrzejewski M.G., et al. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. Biochem Biophys Res Commun 358 (2007) 233-240
22. Liao F., Alkhatib G., Peden K.W., et al. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 185 (1997) 2015-2023
23. Snow R.M., and Schellhammer P.F. Spontaneous regression of metastatic renal cell carcinoma. Urology 20 (1982) 177-181
24. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
25. Costa L.J., and Drabkin H.A. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12 (2007) 1404-1415
26. Esteller M. Epigenetics in cancer. N Engl J Med 358 (2008) 1148-1159
27. Ferber E.C., Kajita M., Wadlow A., et al. A role for the cleaved cytoplasmic domain of E-cadherin in the nucleus. J Biol Chem 283 (2008) 12691-12700
28. Hartmann D., Tournoy J., Saftig P., et al. Implication of APP secretases in notch signaling. J Mol Neurosci 17 (2001) 171-181
29. Meijer J., Ogink J., Kreike B., et al. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res 68 (2008) 4701-4708
30. Lu Y., Wang J., Xu Y., et al. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res 6 (2008) 546-554
31. Held-Feindt J., Rehmke B., Mentlein R., et al. Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas. Glia 56 (2008) 764-774
32. Na I.K., Scheibenbogen C., Adam C., et al. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Human Pathol (2008)
33. Yoshitake N., Fukui H., Yamagishi H., et al. Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Brit J Cancer 98 (2008) 1682-1689
34. Gortz A., Nibbs R.J., McLean P., et al. The chemokine ESkine/CCL27 displays novel modes of intracrine and paracrine function. J Immunol 169 (2002) 1387-1394